The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $84.2 Milion dollars as of 9 January 2020. Advisors Capit owns over 379,997 units of Alector stock worth over $225,474 and over the last 5 years Advisors sold ALEC stock worth over $84,020,261.
Advisors has made over 4 trades of the Alector stock since 2019, according to the Form 4 filled with the SEC. Most recently Advisors sold 1,874,203 units of ALEC stock worth $48,729,278 on 2 March 2020.
The largest trade Advisors's ever made was selling 1,874,203 units of Alector stock on 2 March 2020 worth over $48,729,278. On average, Advisors trades about 931,921 units every 19 days since 2019. As of 9 January 2020 Advisors still owns at least 38,808 units of Alector stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... a Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: